Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...
labmate-online.com7d
Roche and Innovent agree $1billion global licence for a novel DLL3 antibody drug conjugate
Innovent Biologics, a biopharmaceutical company based in Shuzou, China, has agreed a collaboration with Roche to develop ...
TipRanks on MSN7d
Innovent Biologics’ Limertinib Gains Approval for Advanced Lung Cancer Treatment
Innovent Biologics ( ($HK:1801) ) has shared an update. Innovent Biologics announced that its third-generation EGFR TKI, limertinib, has received ...
Vietnam Investment Reviev8d
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 as Monotherapy for Advanced Pancreatic Cancer
Innovent Biologics, Inc., announced that the Center for Drug Evaluation (CDE) of China's National Medical Products ...
GlobalData on MSN7d
CDE grants BTD to Innovent’s IBI343 for pancreatic cancer
"CDE grants BTD to Innovent’s IBI343 for pancreatic cancer" was originally created and published by Pharmaceutical Technology ...
manilatimes7d
Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference
During the conference, Dr. De-Chao Michael Yu, Founder, Chairman and CEO of Innovent, delivered a presentation highlighting ...
Morningstar7d
Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer
SAN FRANCISCO and SUZHOU, China, Jan. 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...
Stockhouse9d
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer
SAN FRANCISCO and SUZHOU, China, Jan. 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
Innovent & ASK Pharm Announce NMPA Approval Of Limertinib,3rd-Gen EGFR TKI For Lung Cancer Treatment
Innovent Biologics Inc. (IVBXF.OB) and Jiangsu Aosaikang Pharmaceutical Co. Ltd. or ASK Pharm announced that China's National Medical ...
Nasdaq7d
Innovent & ASK Pharm Announce NMPA Approval Of Limertinib,3rd-Gen EGFR TKI For Lung Cancer Treatment
(RTTNews) - Innovent Biologics Inc. (IVBXF.OB) and Jiangsu Aosaikang Pharmaceutical Co. Ltd. or ASK Pharm announced that China's National Medical Products Administration (NMPA) has approved the ...